KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Amortization of Deferred Charges (2020 - 2024)

Historic Amortization of Deferred Charges for Guardant Health (GH) over the last 5 years, with Q4 2024 value amounting to $646000.0.

  • Guardant Health's Amortization of Deferred Charges rose 31.06% to $646000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $2.6 million, marking a year-over-year increase of 23.3%. This contributed to the annual value of $2.6 million for FY2024, which is 23.3% up from last year.
  • According to the latest figures from Q4 2024, Guardant Health's Amortization of Deferred Charges is $646000.0, which was up 31.06% from $645000.0 recorded in Q3 2024.
  • Guardant Health's 5-year Amortization of Deferred Charges high stood at $4.7 million for Q4 2020, and its period low was $640000.0 during Q3 2021.
  • Its 5-year average for Amortization of Deferred Charges is $883411.8, with a median of $643000.0 in 2022.
  • Per our database at Business Quant, Guardant Health's Amortization of Deferred Charges tumbled by 8642.42% in 2021 and then soared by 31.25% in 2022.
  • Over the past 5 years, Guardant Health's Amortization of Deferred Charges (Quarter) stood at $4.7 million in 2020, then plummeted by 86.42% to $642000.0 in 2021, then grew by 0.16% to $643000.0 in 2022, then rose by 0.16% to $644000.0 in 2023, then increased by 0.31% to $646000.0 in 2024.
  • Its last three reported values are $646000.0 in Q4 2024, $645000.0 for Q3 2024, and $645000.0 during Q2 2024.